查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1692343

斯塔加特氏症治疗市场 - 全球产业规模、份额、趋势、机会和预测，按药物类型、配销通路、地区和竞争细分，2020-2030 年预测

Stargardt Disease Therapeutics Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, Segmented By Drug Type, By Distribution Channel, By Region & Competition, 2020-2030F
出版日期: | 出版商: TechSci Research | 英文 185 Pages | 商品交期: 2-3个工作天内

价格

We offer 8 hour analyst time for an additional research. Please contact us for the details.

简介目录

2024 年全球 Stargardt 病治疗市场价值为 2.0275 亿美元，预计在预测期内将实现令人印象深刻的增长，到 2030 年的复合年增长率为 7.50%。 Stargardt 病是一种遗传性眼部疾病，在清晰的中央视力中起着至关重要的作用的黄斑部会受到不利影响。这种疾病通常表现在儿童期或青少年期，并逐渐导致视力下降。虽然目前尚无批准的斯塔加特病治疗方法，但在控制病情并可能阻止其进展的治疗方法的开发方面已取得重大进展。例如，世界卫生组织在 2023 年报告称，全球有超过 22 亿人患有视力障碍，其中至少有 10 亿例是可以预防或未解决的。全球失明和视力丧失的主要原因是屈光不正和白内障，凸显了改善眼部护理和预防措施的迫切需求。

市场概况
预测期 2026-2030
2024 年市场规模 2.0275亿美元
2030 年市场规模 3.1041亿美元
2025-2030 年复合年增长率 7.50％
成长最快的领域 LBS-008
最大的市场 北美洲

主要市场驱动因素

盛行率和认知度提高

主要市场挑战

对疾病机制的理解有限

主要市场趋势

基因治疗的突破

目录

第 1 章：产品概述

第 2 章：研究方法

第 3 章：执行摘要

第 4 章：顾客之声

第 5 章：全球 Stargardt 病治疗市场展望

  • 市场规模和预测
    • 按价值
  • 市场占有率和预测
    • 依药物类型（LBS-008、Emixustat）
    • 按配销通路（医院药房、零售药房、网路药房）
    • 按地区
    • 按公司分类（2024）
  • 产品市场图
    • 依药物类型
    • 按配销通路
    • 按地区

第 6 章：北美 Stargardt 病治疗市场展望

  • 市场规模和预测
  • 市场占有率和预测
  • 北美：国家分析
    • 加拿大
    • 墨西哥

第 7 章：欧洲 Stargardt 病治疗市场展望

  • 市场规模和预测
  • 市场占有率和预测
  • 欧洲：国家分析
    • 英国
    • 法国
    • 义大利
    • 西班牙

第 8 章：亚太地区 Stargardt 病治疗市场展望

  • 市场规模和预测
  • 市场占有率和预测
  • 亚太地区：国家分析
    • 日本
    • 印度
    • 澳洲
    • 韩国

第 9 章：南美洲 Stargardt 病治疗市场展望

  • 市场规模和预测
  • 市场占有率和预测
  • 南美洲：国家分析
    • 阿根廷
    • 哥伦比亚

第 10 章：中东和非洲 Stargardt 病治疗市场展望

  • 市场规模和预测
  • 市场占有率和预测
  • MEA：国家分析
    • 沙乌地阿拉伯
    • 阿联酋
    • 科威特

第 11 章：市场动态

  • 驱动程式
  • 挑战

第 12 章：市场趋势与发展

  • 近期发展
  • 合併与收购
  • 产品发布

第 13 章：波特五力分析

  • 产业竞争
  • 新进入者的潜力
  • 供应商的力量
  • 顾客的力量
  • 替代产品的威胁

第 14 章：竞争格局

  • Kubota Pharmaceutical Holdings Co Ltd
  • IVERIC bio Inc
  • Sanofi SA
  • Alkeus Pharmaceuticals Inc
  • Astellas Pharma Inc
  • Cha Biotech Co Ltd/Old
  • reVision Therapeutics, Inc.
  • Biogen Inc
  • F Hoffmann-La Roche AG
  • Ocugen Inc

第 15 章：策略建议

第16章调查会社について・免责事项

简介目录
Product Code: 18728

Global Stargardt Disease Therapeutics Market was valued at USD 202.75 million in 2024 and is anticipated to project impressive growth in the forecast period with a CAGR of 7.50% through 2030. In Stargardt disease, an inherited eye condition, the macula, which plays a crucial role in clear central vision, is adversely affected. This condition typically manifests in childhood or adolescence and gradually leads to a decline in visual acuity. While there are currently no approved treatments for Stargardt disease, significant progress has been made in the development of therapeutic approaches aimed at managing the condition and potentially arresting its progression. For instance, in 2023, WHO reported that over 2.2 billion people worldwide have vision impairment, with at least 1 billion cases preventable or unaddressed. The primary causes of blindness and vision loss globally are refractive errors and cataracts, highlighting the urgent need for improved eye care and preventive measures.

Market Overview
Forecast Period2026-2030
Market Size 2024USD 202.75 Million
Market Size 2030USD 310.41 Million
CAGR 2025-20307.50%
Fastest Growing SegmentLBS-008
Largest MarketNorth America

Key Market Drivers

Increased Prevalence and Awareness

The prevalence of Stargardt Disease has been on the rise, with an increasing number of individuals being diagnosed with this condition worldwide. While it remains a rare disease, the broader global population and improved diagnostic capabilities have led to more cases being identified. This heightened prevalence underscores the urgency of finding effective treatments and therapies for those affected. For instance, in 2025, Ascidian Therapeutics has received FDA authorization to begin a Phase 1/2 clinical trial for ACDN-01, its RNA editing therapy for Stargardt disease, a genetic eye disorder caused by ABCA4 mutations. Unlike traditional gene therapies, ACDN-01 rewrites RNA exons to restore healthy protein production, potentially benefiting many affected individuals.

Stargardt Disease primarily affects children and young adults, but the ageing population has also contributed to its increasing prevalence. As the global population continues to age, the demand for treatments for age-related eye conditions, including Stargardt Disease, is expected to grow significantly. This demographic shift amplifies the market potential for Stargardt Disease therapeutics.

Key Market Challenges

Limited Understanding of the Disease Mechanism

Despite significant progress, our understanding of the exact mechanisms underlying Stargardt Disease remains incomplete. This knowledge gap can impede the development of targeted therapies and necessitates ongoing research to uncover the complexities of the condition.

Key Market Trends

Gene Therapy Breakthroughs

Gene therapy is emerging as a promising avenue in the quest to treat Stargardt Disease. Researchers are conducting clinical trials to test the safety and efficacy of gene therapies that aim to replace or correct the faulty genes responsible for the condition. As trials progress, breakthroughs that bring gene therapy closer to becoming a viable treatment option are likely to come up.

Key Market Players

  • Kubota Pharmaceutical Holdings Co Ltd
  • IVERIC bio Inc
  • Sanofi SA
  • Alkeus Pharmaceuticals Inc
  • Astellas Pharma Inc
  • Cha Biotech Co Ltd/Old
  • reVision Therapeutics, Inc.
  • Biogen Inc
  • F Hoffmann-La Roche AG
  • Ocugen Inc

Report Scope:

In this report, the Global Stargardt Disease Therapeutics Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Stargardt Disease Therapeutics Market, By Drug Type:

  • LBS-008
  • Emixustat

Stargardt Disease Therapeutics Market, By Distribution Channel:

  • Hospital Pharmacies
  • Retail Pharmacies
  • Online Pharmacies

Stargardt Disease Therapeutics Market, By Region:

  • North America
    • United States
    • Canada
    • Mexico
  • Europe
    • Germany
    • United Kingdom
    • France
    • Italy
    • Spain
  • Asia-Pacific
    • China
    • Japan
    • India
    • Australia
    • South Korea
  • South America
    • Brazil
    • Argentina
    • Colombia
  • Middle East & Africa
    • South Africa
    • Saudi Arabia
    • UAE
    • Kuwait

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global Stargardt Disease Therapeutics Market.

Available Customizations:

Global Stargardt Disease Therapeutics market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

  • Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

  • 1.1. Market Definition
  • 1.2. Scope of the Market
    • 1.2.1. Markets Covered
    • 1.2.2. Years Considered for Study
    • 1.2.3. Key Market Segmentations

2. Research Methodology

  • 2.1. Objective of the Study
  • 2.2. Baseline Methodology
  • 2.3. Key Industry Partners
  • 2.4. Major Association and Secondary Sources
  • 2.5. Forecasting Methodology
  • 2.6. Data Triangulation & Validation
  • 2.7. Assumptions and Limitations

3. Executive Summary

  • 3.1. Overview of the Market
  • 3.2. Overview of Key Market Segmentations
  • 3.3. Overview of Key Market Players
  • 3.4. Overview of Key Regions/Countries
  • 3.5. Overview of Market Drivers, Challenges, Trends

4. Voice of Customer

5. Global Stargardt Disease Therapeutics Market Outlook

  • 5.1. Market Size & Forecast
    • 5.1.1. By Value
  • 5.2. Market Share & Forecast
    • 5.2.1. By Drug Type (LBS-008, Emixustat)
    • 5.2.2. By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies)
    • 5.2.3. By Region
    • 5.2.4. By Company (2024)
  • 5.3. Product Market Map
    • 5.3.1. By Drug Type
    • 5.3.2. By Distribution Channel
    • 5.3.3. By Region

6. North America Stargardt Disease Therapeutics Market Outlook

  • 6.1. Market Size & Forecast
    • 6.1.1. By Value
  • 6.2. Market Share & Forecast
    • 6.2.1. By Drug Type (LBS-008, Emixustat)
    • 6.2.2. By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies)
    • 6.2.3. By Country
  • 6.3. North America: Country Analysis
    • 6.3.1. United States Stargardt Disease Therapeutics Market Outlook
      • 6.3.1.1. Market Size & Forecast
        • 6.3.1.1.1. By Value
      • 6.3.1.2. Market Share & Forecast
        • 6.3.1.2.1. By Drug Type
        • 6.3.1.2.2. By Distribution Channel
    • 6.3.2. Canada Stargardt Disease Therapeutics Market Outlook
      • 6.3.2.1. Market Size & Forecast
        • 6.3.2.1.1. By Value
      • 6.3.2.2. Market Share & Forecast
        • 6.3.2.2.1. By Drug Type
        • 6.3.2.2.2. By Distribution Channel
    • 6.3.3. Mexico Stargardt Disease Therapeutics Market Outlook
      • 6.3.3.1. Market Size & Forecast
        • 6.3.3.1.1. By Value
      • 6.3.3.2. Market Share & Forecast
        • 6.3.3.2.1. By Drug Type
        • 6.3.3.2.2. By Distribution Channel

7. Europe Stargardt Disease Therapeutics Market Outlook

  • 7.1. Market Size & Forecast
    • 7.1.1. By Value
  • 7.2. Market Share & Forecast
    • 7.2.1. By Drug Type (LBS-008, Emixustat)
    • 7.2.2. By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies)
    • 7.2.3. By Country
  • 7.3. Europe: Country Analysis
    • 7.3.1. Germany Stargardt Disease Therapeutics Market Outlook
      • 7.3.1.1. Market Size & Forecast
        • 7.3.1.1.1. By Value
      • 7.3.1.2. Market Share & Forecast
        • 7.3.1.2.1. By Drug Type
        • 7.3.1.2.2. By Distribution Channel
    • 7.3.2. United Kingdom Stargardt Disease Therapeutics Market Outlook
      • 7.3.2.1. Market Size & Forecast
        • 7.3.2.1.1. By Value
      • 7.3.2.2. Market Share & Forecast
        • 7.3.2.2.1. By Drug Type
        • 7.3.2.2.2. By Distribution Channel
    • 7.3.3. France Stargardt Disease Therapeutics Market Outlook
      • 7.3.3.1. Market Size & Forecast
        • 7.3.3.1.1. By Value
      • 7.3.3.2. Market Share & Forecast
        • 7.3.3.2.1. By Drug Type
        • 7.3.3.2.2. By Distribution Channel
    • 7.3.4. Italy Stargardt Disease Therapeutics Market Outlook
      • 7.3.4.1. Market Size & Forecast
        • 7.3.4.1.1. By Value
      • 7.3.4.2. Market Share & Forecast
        • 7.3.4.2.1. By Drug Type
        • 7.3.4.2.2. By Distribution Channel
    • 7.3.5. Spain Stargardt Disease Therapeutics Market Outlook
      • 7.3.5.1. Market Size & Forecast
        • 7.3.5.1.1. By Value
      • 7.3.5.2. Market Share & Forecast
        • 7.3.5.2.1. By Drug Type
        • 7.3.5.2.2. By Distribution Channel

8. Asia-Pacific Stargardt Disease Therapeutics Market Outlook

  • 8.1. Market Size & Forecast
    • 8.1.1. By Value
  • 8.2. Market Share & Forecast
    • 8.2.1. By Drug Type (LBS-008, Emixustat)
    • 8.2.2. By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies)
    • 8.2.3. By Country
  • 8.3. Asia-Pacific: Country Analysis
    • 8.3.1. China Stargardt Disease Therapeutics Market Outlook
      • 8.3.1.1. Market Size & Forecast
        • 8.3.1.1.1. By Value
      • 8.3.1.2. Market Share & Forecast
        • 8.3.1.2.1. By Drug Type
        • 8.3.1.2.2. By Distribution Channel
    • 8.3.2. Japan Stargardt Disease Therapeutics Market Outlook
      • 8.3.2.1. Market Size & Forecast
        • 8.3.2.1.1. By Value
      • 8.3.2.2. Market Share & Forecast
        • 8.3.2.2.1. By Drug Type
        • 8.3.2.2.2. By Distribution Channel
    • 8.3.3. India Stargardt Disease Therapeutics Market Outlook
      • 8.3.3.1. Market Size & Forecast
        • 8.3.3.1.1. By Value
      • 8.3.3.2. Market Share & Forecast
        • 8.3.3.2.1. By Drug Type
        • 8.3.3.2.2. By Distribution Channel
    • 8.3.4. Australia Stargardt Disease Therapeutics Market Outlook
      • 8.3.4.1. Market Size & Forecast
        • 8.3.4.1.1. By Value
      • 8.3.4.2. Market Share & Forecast
        • 8.3.4.2.1. By Drug Type
        • 8.3.4.2.2. By Distribution Channel
    • 8.3.5. South Korea Stargardt Disease Therapeutics Market Outlook
      • 8.3.5.1. Market Size & Forecast
        • 8.3.5.1.1. By Value
      • 8.3.5.2. Market Share & Forecast
        • 8.3.5.2.1. By Drug Type
        • 8.3.5.2.2. By Distribution Channel

9. South America Stargardt Disease Therapeutics Market Outlook

  • 9.1. Market Size & Forecast
    • 9.1.1. By Value
  • 9.2. Market Share & Forecast
    • 9.2.1. By Drug Type (LBS-008, Emixustat)
    • 9.2.2. By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies)
    • 9.2.3. By Country
  • 9.3. South America: Country Analysis
    • 9.3.1. Brazil Stargardt Disease Therapeutics Market Outlook
      • 9.3.1.1. Market Size & Forecast
        • 9.3.1.1.1. By Value
      • 9.3.1.2. Market Share & Forecast
        • 9.3.1.2.1. By Drug Type
        • 9.3.1.2.2. By Distribution Channel
    • 9.3.2. Argentina Stargardt Disease Therapeutics Market Outlook
      • 9.3.2.1. Market Size & Forecast
        • 9.3.2.1.1. By Value
      • 9.3.2.2. Market Share & Forecast
        • 9.3.2.2.1. By Drug Type
        • 9.3.2.2.2. By Distribution Channel
    • 9.3.3. Colombia Stargardt Disease Therapeutics Market Outlook
      • 9.3.3.1. Market Size & Forecast
        • 9.3.3.1.1. By Value
      • 9.3.3.2. Market Share & Forecast
        • 9.3.3.2.1. By Drug Type
        • 9.3.3.2.2. By Distribution Channel

10. Middle East and Africa Stargardt Disease Therapeutics Market Outlook

  • 10.1. Market Size & Forecast
    • 10.1.1. By Value
  • 10.2. Market Share & Forecast
    • 10.2.1. By Drug Type (LBS-008, Emixustat)
    • 10.2.2. By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies)
    • 10.2.3. By Country
  • 10.3. MEA: Country Analysis
    • 10.3.1. South Africa Stargardt Disease Therapeutics Market Outlook
      • 10.3.1.1. Market Size & Forecast
        • 10.3.1.1.1. By Value
      • 10.3.1.2. Market Share & Forecast
        • 10.3.1.2.1. By Drug Type
        • 10.3.1.2.2. By Distribution Channel
    • 10.3.2. Saudi Arabia Stargardt Disease Therapeutics Market Outlook
      • 10.3.2.1. Market Size & Forecast
        • 10.3.2.1.1. By Value
      • 10.3.2.2. Market Share & Forecast
        • 10.3.2.2.1. By Drug Type
        • 10.3.2.2.2. By Distribution Channel
    • 10.3.3. UAE Stargardt Disease Therapeutics Market Outlook
      • 10.3.3.1. Market Size & Forecast
        • 10.3.3.1.1. By Value
      • 10.3.3.2. Market Share & Forecast
        • 10.3.3.2.1. By Drug Type
        • 10.3.3.2.2. By Distribution Channel
    • 10.3.4. Kuwait Stargardt Disease Therapeutics Market Outlook
      • 10.3.4.1. Market Size & Forecast
        • 10.3.4.1.1. By Value
      • 10.3.4.2. Market Share & Forecast
        • 10.3.4.2.1. By Drug Type
        • 10.3.4.2.2. By Distribution Channel

11. Market Dynamics

  • 11.1. Drivers
  • 11.2. Challenges

12. Market Trends & Developments

  • 12.1. Recent Development
  • 12.2. Mergers & Acquisitions
  • 12.3. Product Launches

13. Porter's Five Forces Analysis

  • 13.1. Competition in the Industry
  • 13.2. Potential of New Entrants
  • 13.3. Power of Suppliers
  • 13.4. Power of Customers
  • 13.5. Threat of Substitute Products

14. Competitive Landscape

  • 14.1. Kubota Pharmaceutical Holdings Co Ltd
    • 14.1.1. Business Overview
    • 14.1.2. Product Offerings
    • 14.1.3. Recent Developments
    • 14.1.4. Financials (As Reported)
    • 14.1.5. Key Personnel
    • 14.1.6. SWOT Analysis
  • 14.2. IVERIC bio Inc
  • 14.3. Sanofi SA
  • 14.4. Alkeus Pharmaceuticals Inc
  • 14.5. Astellas Pharma Inc
  • 14.6. Cha Biotech Co Ltd/Old
  • 14.7. reVision Therapeutics, Inc.
  • 14.8. Biogen Inc
  • 14.9. F Hoffmann-La Roche AG
  • 14.10.Ocugen Inc

15. Strategic Recommendations

16. About Us & Disclaimer